| Literature DB >> 31485450 |
Marco Meloni1, Valentina Izzo1, Laura Giurato1, Enrico Brocco2, Michele Ferrannini3, Roberto Gandini4, Luigi Uccioli1,2.
Abstract
AIM: To evaluate the prognostic role of procalcitonin (PCT) in patients with diabetic foot infection (DFI) and critical limb ischemia (CLI).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31485450 PMCID: PMC6710766 DOI: 10.1155/2019/4312737
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Baseline characteristic of the whole population.
| Variables | Whole population ( |
|---|---|
| Age (years) | 67.3 ± 11.4 |
| Sex (male) | 80.7% |
| Diabetes (type 2) | 95.1% |
| Diabetes duration (years) | 20.5 ± 11.1 |
| HbA1c (mmol/mol) (%) | 67 ± 16 (8.3 ± 3.6) |
| Hypertension (yes) | 73.1% |
| Dyslipidemia (yes) | 72.1% |
| Current smokers | 11.1% |
| IHD | 72.8% |
| Heart failure | 27.9% |
| CAD | 15.8% |
| ESRD (dialysis) | 37.2% |
| Procalcitonin (ng/ml) | 1.3 ± 0.3 |
| ESR (mm/h) | 104 ± 14 |
| CRP (mg/dl) | 85.6 ± 47.8 |
| WBC (×103/ml) | 11.3 ± 2.5 |
| Fibrinogen (mg/ml) | 455 ± 165 |
| Wound parameters | |
| Dimension (>5 cm2) | 83.1% |
| TcPO2 basal (mmHg) | 22.4 ± 7.9 |
IHD: Ischemic heart disease; CAD: carotid artery disease; ESRD: end-stage renal disease; ESR: erythrocyte sedimentation rate; CRP: c-reactive protein; TcPO2: transcutaneous foot oximetry; WBC: white blood cells; PTA: percutaneous transluminal angioplasty.
Positivity of procalcitonin according to the degree of infection and comorbidities.
| Variables | Positive procalcitonin | Normal procalcitonin |
|
|---|---|---|---|
| Moderate infection | 15/23 (65.2%) | — | |
| Severe infection | 8/23 (34.8%) | — | |
| ESRD | 13/23 (56.5%) | 19/63 (30.1%) | 0.0002 |
| IHD | 17/23 (73.9%) | 45/63 (71.4%) | 0.2 |
| Heart failure | 12/23 (52.2%) | 12/63 (19%) | 0.0001 |
ESRD: End-stage renal disease; IHD: ischemic heart disease.
Figure 1Hospital outcomes in patients with or without positive values of PCT. PCT: procalcitonin.
Relation between baseline inflammatory markers and outcomes.
| Inflammatory markers | Survival with MA | Survival without MA |
| Survivors | Deceased |
|
|---|---|---|---|---|---|---|
| WBC (×103/ml) | 10.9 ± 1.6 | 11.3 ± 2.4 | 0.1 | 11.2 ± 2.1 | 11.5 ± 1.8 | 0.2 |
| CRP (mg/dl) | 90 ± 27 | 87.7 ± 34 | 0.3 | 87.9 ± 33 | 100.8 ± 55 | 0.04 |
| ESR (mm/h) | 108 ± 17 | 104 ± 13 | 0.8 | 104 ± 14 | 110 ± 9 | 0.08 |
| Fibrinogen | 462 ± 190 | 452 ± 158 | 0.07 | 453 ± 164 | 466 ± 195 | 0.06 |
MA: Major amputation; WCB: white blood cells; CRP: c-reactive protein; ESR: erythrocyte sedimentation rate.